Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 11/20 | 0.86 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.67 |
| ▸ | MAOB | P27338 | 6/20 | 0.61 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5038595 | 0.88 | FFAR1 (0.68) | FFAR1NR4A2MAOBPARP10 | |
| SCHEMBL28284959 | 0.85 | FFAR1 (0.85) | FFAR1NR4A2MAOB | |
| SCHEMBL5038715 | 0.85 | FFAR1 (0.64) | FFAR1NR4A2MAOBPARP10 | |
| SCHEMBL5152185 | 0.84 | FFAR1 (0.83) | FFAR1NR4A2MAOBPARP10 | |
| SCHEMBL31591490 | 0.80 | NR4A2 (1.00) | NR4A2MAOBPARP10 | |
| SCHEMBL2195021 | 0.80 | NR4A2 (1.00) | NR4A2MAOBPARP10 | |
| SCHEMBL3498062 | 0.79 | NR4A2 (0.72) | FFAR1NR4A2MAOBPARP10 | |
| SCHEMBL9935151 | 0.79 | FFAR1 (1.00) | FFAR1 | |
| SCHEMBL5947379 | 0.78 | FFAR1 (0.88) | FFAR1NR4A2 | |
| SCHEMBL4426248 | 0.78 | NR4A2 (0.70) | FFAR1NR4A2MAOBPARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1523469-B1 | CINNAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-10-08 | — | — | EP | disclosed |
| CN-1305838-C | Cinnamide derivatives | HOFFMANN LA ROCHE (CH) | 2007-03-21 | — | — | CN | disclosed |
| CN-1665774-A | cinnamide derivative | HOFFMANN LA ROCHE (CH) | 2005-09-07 | — | — | CN | disclosed |
| US-6900354-B2 | 3-phenyl-propionamido, 3-phenyl-acrylamido and 3-phenyl-propynamido derivatives | HOFFMAN-LA ROCHE INC. (US) | 2005-05-31 | — | — | US | disclosed |
| EP-1523469-A1 | CINNAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-04-20 | — | — | EP | disclosed |
| US-20040034096-A1 | 3-Phenyl-propionamido, 3-phenyl-acrylamido and 3-phenyl-propynamido derivatives | HOFFMANN-LA ROCHE INC. | 2004-02-19 | — | — | US | disclosed |
| WO-2004007429-A1 | CINNAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034096-A1 | 3-Phenyl-propionamido, 3-phenyl-acrylamido and 3-phenyl-propynamido derivatives | MAOB, MAOA, APP | FFAR1 2999/4885NR4A2 2679/4885MAOB 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.